-+ 0.00%
-+ 0.00%
-+ 0.00%

China's National Medical Products Administration Has Approved GSK's Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Inadequately Controlled Chronic Obstructive Pulmonary Disease

Benzinga·01/05/2026 09:17:45
Listen to the news
  • Nucala is the first and only monthly biologic approved in China studied in a wide COPD population with blood eosinophil count (BEC) starting as low as 150 cells/µL.
  • Approval based on the positive MATINEE and METREX phase III trials
  • MATINEE data included reduction of exacerbations leading to hospitalisation and/or emergency department visits
  • Of patients inadequately controlled on inhaled triple therapy, 67% have a blood eosinophil count above 150 cells/µL